Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA approved Eisai's intravenous sedative-hypnotic agent Lusedra (fospropofol), but without the marketing advantage the company was hoping it would used to help differentiate the anesthetic from its competitors

You may also be interested in...



Eisai Sees Generics Opportunity In Japan For Innovator Companies

A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito

Eisai Sees Generics Opportunity In Japan For Innovator Companies

A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito

U.S. FDA Rejects Eisai’s Aquavan Injection

Despite a recent advisory panel vote recommending clearance, albeit with strings attached, U.S. FDA has deemed Eisai's Aquavan, a mild-to-moderate sedative for colonoscopies and other procedures, "not approvable.

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel